Zephyr AI launches its big data and machine learning methods to assist precision medicine
Technology investment company and incubator Red Cell Partners today announced the launch of Zephyr AI, which uses big data Collection to provide information for clinical care and the development of new targeted precision therapies.
The new company's management team is made up of Yisroel Brumer, CEO of the former Defense Secretary's Office; Executive Chairman Grant Verstandig, most recently Chief Digital Officer at UnitedHealth Group; and Chief Technology Officer Jeff Sherman, a machine learning architect at Rally Health, which was acquired by UnitedHealth's Optum division in 2017.
According to the press release announced, Zephyr AI will improve patient effectiveness and reduce costs by combining artificial intelligence with a wide range of data sets to upend traditional 'guess and test' drug development and personalized medical processes to explore new treatments and applications. " Existing treatments, as well as advanced biomarkers for personalized treatment. "
The potential start-up hinted at its direction earlier this year through two papers published by its founder in Oncogene magazine detailing the company's technology and performance.
"these findings show that Zephyr AI has been able to identify new use cases for existing cancer treatments," said Sherman, the company's chief technology officer. "the progress we have made in the months since its publication has been astonishing. This is proof to our Zephyr AI team and a small part of the breakthrough that is about to be made."
While seeking to leverage its technology, the company is focused on building industry partnerships that enable it to collect and analyze large-scale data sets to help it develop machine learning pipelines. This will enable the company to work with drug developers to explore a variety of different ways, including saving orphan drugs, creating new treatment combinations and reusing existing drugs for new uses.
"although drug development has always used the best scientific processes available, these processes are so slow that patients waiting for new treatments lose hope. Zephyr AI will take a targeted approach to its technology to accelerate discovery, "Jack Rowe, a member of Zephyr AI's board and former chief executive of Aetna, said in a press release." Pharmaceuticals, biotechnology and payers are enthusiastic about the work we do. They understand that our model of promoting precision care is the future of drug development. "
In addition, Zephyr AI intends to become a participant in biomarker discovery to help patients choose existing and developing treatments as new participants in the fast-growing field of clinical trial optimization. The company will use its artificial intelligence tools to match patients with treatments based on their specific disease characteristics.
